ALDX
Aldeyra Therapeutics Inc

8,095
Mkt Cap
$292.39M
Volume
560,401.00
52W High
$7.20
52W Low
$1.14
PE Ratio
-6.73
ALDX Fundamentals
Price
$4.73
Prev Close
$4.86
Open
$4.99
50D MA
$5.19
Beta
2.68
Avg. Volume
671,710.13
EPS (Annual)
-$0.9389
P/B
5.94
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Savant Capital LLC Makes New $552,000 Investment in Aldeyra Therapeutics, Inc. $ALDX
Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...
Business Wire·7d ago
News Placeholder
Aldeyra Therapeutics (NASDAQ:ALDX) Given Buy Rating at BTIG Research
BTIG Research reissued a "buy" rating and issued a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday...
MarketBeat·9d ago
News Placeholder
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...
Business Wire·9d ago
News Placeholder
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the...
MarketBeat·14d ago
News Placeholder
Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development
Stocktwits·23d ago
News Placeholder
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...
Business Wire·24d ago
News Placeholder
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Zacks·4mo ago
News Placeholder
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Zacks·4mo ago
News Placeholder
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·4mo ago

Latest ALDX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.